Back to Search
Start Over
Rosiglitazone disrupts pancreatic ductal adenocarcinoma progression by activating the tumor suppressor ESE3/EHF.
- Source :
-
Cancer biology & medicine [Cancer Biol Med] 2022 Jul 21. Date of Electronic Publication: 2022 Jul 21. - Publication Year :
- 2022
- Publisher :
- Ahead of Print
-
Abstract
- Competing Interests: No potential conflicts of interest are disclosed.
Details
- Language :
- English
- ISSN :
- 2095-3941
- Database :
- MEDLINE
- Journal :
- Cancer biology & medicine
- Publication Type :
- Editorial & Opinion
- Accession number :
- 35856565
- Full Text :
- https://doi.org/10.20892/j.issn.2095-3941.2022.0299